Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29


Efficacy of affibody-based ultrasound molecular imaging of vascular B7-H3 for breast cancer detection.

Bam R, Lown PS, Stern LA, Sharma K, Wilson KE, Bean GR, Lutz AM, Paulmurugan R, Hackel BJ, Dahl J, Abou-Elkacem L.

Clin Cancer Res. 2020 Jan 10. pii: clincanres.1655.2019. doi: 10.1158/1078-0432.CCR-19-1655. [Epub ahead of print]


Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.

Harrison BT, Fowler E, Krings G, Chen YY, Bean GR, Vincent-Salomon A, Fuhrmann L, Barnick SE, Chen B, Hosfield EM, Hornick JL, Schnitt SJ.

Am J Surg Pathol. 2019 Dec;43(12):1693-1700. doi: 10.1097/PAS.0000000000001366.


Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.

Mukhtar RA, Holland M, Sieber DA, Wen KW, Rugo HS, Kadin ME, Bean GR.

Plast Reconstr Surg Glob Open. 2019 Apr 4;7(4):e2188. doi: 10.1097/GOX.0000000000002188. eCollection 2019 Apr.


CRTC1-MAML2 fusion in mucoepidermoid carcinoma of the breast.

Bean GR, Krings G, Otis CN, Solomon DA, García JJ, van Zante A, Camelo-Piragua S, van Ziffle J, Chen YY.

Histopathology. 2019 Feb;74(3):463-473. doi: 10.1111/his.13779. Epub 2018 Dec 5.


DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation.

Bean GR, Anderson J, Sangoi AR, Krings G, Garg K.

Mod Pathol. 2019 Feb;32(2):280-289. doi: 10.1038/s41379-018-0132-5. Epub 2018 Sep 28.


Recurrent GNA14 mutations in anastomosing haemangiomas.

Bean GR, Joseph NM, Folpe AL, Horvai AE, Umetsu SE.

Histopathology. 2018 Aug;73(2):354-357. doi: 10.1111/his.13519. Epub 2018 May 21. No abstract available.


Adipocyte size variability in benign and malignant lipomatous tumors and morphologic mimics: a quantitative definition using digital pathology.

Bean GR, Wen KW, Horvai AE.

Hum Pathol. 2018 Feb;72:52-58. doi: 10.1016/j.humpath.2017.10.030. Epub 2017 Nov 9.


Fibroepithelial lesions; The WHO spectrum.

Krings G, Bean GR, Chen YY.

Semin Diagn Pathol. 2017 Sep;34(5):438-452. doi: 10.1053/j.semdp.2017.05.006. Epub 2017 May 28. Review.


Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.

Krings G, Joseph NM, Bean GR, Solomon D, Onodera C, Talevich E, Yeh I, Grenert JP, Hosfield E, Crawford ED, Jordan RC, van Zante A, Zaloudek C, Shin SJ, Chen YY.

Mod Pathol. 2017 Aug;30(8):1086-1099. doi: 10.1038/modpathol.2017.32. Epub 2017 May 26.


Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.

Kremer JC, Prudner BC, Lange SES, Bean GR, Schultze MB, Brashears CB, Radyk MD, Redlich N, Tzeng SC, Kami K, Shelton L, Li A, Morgan Z, Bomalaski JS, Tsukamoto T, McConathy J, Michel LS, Held JM, Van Tine BA.

Cell Rep. 2017 Jan 24;18(4):991-1004. doi: 10.1016/j.celrep.2016.12.077.


Recurrent GNAQ mutations in anastomosing hemangiomas.

Bean GR, Joseph NM, Gill RM, Folpe AL, Horvai AE, Umetsu SE.

Mod Pathol. 2017 May;30(5):722-727. doi: 10.1038/modpathol.2016.234. Epub 2017 Jan 13.


A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.

Bean GR, Kremer JC, Prudner BC, Schenone AD, Yao JC, Schultze MB, Chen DY, Tanas MR, Adkins DR, Bomalaski J, Rubin BP, Michel LS, Van Tine BA.

Cell Death Dis. 2016 Oct 13;7(10):e2406. doi: 10.1038/cddis.2016.232.


PUMA and BIM are required for oncogene inactivation-induced apoptosis.

Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH.

Sci Signal. 2013 Mar 26;6(268):ra20. doi: 10.1126/scisignal.2003483.


BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program.

Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH.

Science. 2010 Dec 3;330(6009):1390-3. doi: 10.1126/science.1190217.


CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.

Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):901-14. doi: 10.1158/1055-9965.EPI-08-0875. Epub 2009 Mar 3.


ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884-90. doi: 10.1158/1055-9965.EPI-07-2696.


Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF.

Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC Jr, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6834-41.


Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.

Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, Zalles C, Lipkus IM.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1032-4.


Overweight and obese perimenopausal and postmenopausal women exhibit increased abnormal mammary epithelial cytology.

Seewaldt VL, Goldenberg V, Jones LW, Peace C, Broadwater G, Scott V, Bean GR, Wilke LG, Zalles CM, Demark-Wahnefried W.

Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):613-6.


Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.

Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC Jr, Troch MM, Paisie C, Wilke LG, Yee L, Marcom PK, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Scott V, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):50-6.


Long-term raloxifene in a woman at high risk for breast cancer.

Bean GR, Kimler BF, Seewaldt VL.

N Engl J Med. 2006 Oct 12;355(15):1620-2. No abstract available.


Interferon regulatory factor-1 regulates reconstituted extracellular matrix (rECM)-mediated apoptosis in human mammary epithelial cells.

Bowie ML, Troch MM, Delrow J, Dietze EC, Bean GR, Ibarra C, Pandiyan G, Seewaldt VL.

Oncogene. 2007 Mar 29;26(14):2017-26. Epub 2006 Oct 2.


CREB-binding protein regulates apoptosis and growth of HMECs grown in reconstituted ECM via laminin-5.

Dietze EC, Bowie ML, Mrózek K, Caldwell LE, Neal C, Marjoram RJ, Troch MM, Bean GR, Yokoyama KK, Ibarra CA, Seewaldt VL.

J Cell Sci. 2005 Nov 1;118(Pt 21):5005-22. Epub 2005 Oct 11.


Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration.

Bean GR, Scott V, Yee L, Ratliff-Daniel B, Troch MM, Seo P, Bowie ML, Marcom PK, Slade J, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Baker JC Jr, Wilke LG, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):790-8.


Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells.

Bowie ML, Dietze EC, Delrow J, Bean GR, Troch MM, Marjoram RJ, Seewaldt VL.

Oncogene. 2004 Nov 18;23(54):8743-55.


Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Ratliff B, Dietze EC, Bean GR, Moore C, Wanko S, Seewaldt VL.

J Natl Cancer Inst. 2004 Jun 2;96(11):883; author reply 884-5. No abstract available.


Tamoxifen and tamoxifen ethyl bromide induce apoptosis in acutely damaged mammary epithelial cells through modulation of AKT activity.

Dietze EC, Troch MM, Bean GR, Heffner JB, Bowie ML, Rosenberg P, Ratliff B, Seewaldt VL.

Oncogene. 2004 May 6;23(21):3851-62.


CBP/p300 induction is required for retinoic acid sensitivity in human mammary cells.

Dietze EC, Troch MM, Bowie ML, Yee L, Bean GR, Seewaldt VL.

Biochem Biophys Res Commun. 2003 Mar 21;302(4):841-8.


Retinoids and retinoic acid receptors regulate growth arrest and apoptosis in human mammary epithelial cells and modulate expression of CBP/p300.

Dietze EC, Caldwell LE, Marcom K, Collins SJ, Yee L, Swisshelm K, Hobbs KB, Bean GR, Seewaldt VL.

Microsc Res Tech. 2002 Oct 1;59(1):23-40.


Supplemental Content

Support Center